# Caihe Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/caihe-biotech

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.caihepharm.com
- Latest round: Series A (Sep 4, 2025)
- Investors on record: 1

## About

Caihe Biotech, located in Hangzhou, China, specializes in the research, development, manufacturing, and sale of pharmaceutical products, focusing on food additives and active pharmaceutical ingredients.Founded in 2019 in Hangzhou, China, Caihe Biotech is engaged in the pharmaceutical industry, particularly in food additives and APIs. The company has completed one deal, and its most recent funding round was on September 4, 2025, targeting investment for product innovation and R&D. There is no mention of changes in business strategy or any subsidiaries.Zhejiang Caihe Biotech Co., Ltd. focuses on researching, developing, manufacturing, and selling pharmaceutical products such as food additives, active pharmaceutical ingredients, and high-level pharmaceutical intermediates. The company has established a robust production process that emphasizes innovation and environmental sustainability, targeting diverse markets, particularly in North America and Europe. Their offerings cater to pharmaceutical manufacturers and food production companies, supported by advanced laboratory equipment and a commitment to technical enhancement.Zhejiang Caihe Biotech Co., Ltd. generates revenue through direct B2B sales of its pharmaceutical products to clients in the pharmaceutical manufacturing and food production sectors. Their structured pricing model reflects the quality and complexity of their flagship products, including food additives and APIs. Strategic partnerships with distributors and wholesalers enhance their market reach, although specific product pricing plans are not publicly disclosed.Caihe Biotech aims to utilize the funding raised in September 2025 from Jiangsu Jinqiao Private Equity Fund Management to enhance its R&D, innovation, manufacturing, and marketing of pharmaceutical products. The company is expected to focus on launching new products and expanding into North American and European markets, although specific product launch dates have not been provided.

## Funding rounds

- Series A, Sep 4, 2025 — Jiangsu Jinqiao Private Equity Fund Management

## Investors

- Jiangsu Jinqiao Private Equity Fund Management (https://capitalatlas.ai/funds/jiangsu-jinqiao-private-equity-fund-management) — Series A